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1. Abstract  
Therapy resistance of malignant cells represents the main reason responsible for the failure 
of cancer therapy. The growth of malignant cells at primary tumour sites but most 
importantly the dissemination of tumour cells and their growth at secondary sites, are the 
main reasons why patients eventually succumb to the disease. Even novel immune-based 
therapies find their limitation in most tumour types. The therapy resistance is mediated by 
the tumour cells but also by other cellular components of the tumour microenvironment. 
Understanding the tumour cells mechanisms and the tumour microenvironment features 
responsible for therapy resistance enables the development of novel therapeutic strategies.  
Here, we show that ionizing irradiation, 5-azacytidine, and IFNγ treatments induced 
expression of suprabasin (SBSN) and therapy-resistant low-adherent phenotype in cancer 
cells. Knockdown of SBSN resulted in suppression of the phenotype. Next, we identified 
aberrantly elevated SBSN in the bone marrow of a subgroup of myelodysplastic syndromes 
(MDS) patients. SBSN was expressed by myeloid-derived suppressor cells (MDSCs) and 
showed significant anti-correlation with T cell abundance and CCL2 levels, hence 
promises a prognostic value in clinical use. We compiled the most of the relevant 
knowledge of SBSN together with our results. Data presented in this thesis point to an 
important role of SBSN oncogene in therapy resistance and its diagnostic and prognostic 
potential in MDS.  
 
Abstrakt  
Rezistence nádorových buněk vůči léčbě představuje hlavní důvod neúspěšné nádorové 
terapie. Růst nádorových buněk v primárním místě nádoru nebo jejich šíření a růst  
v sekundárních oblastech jsou hlavní důvody, proč pacienti nemoci podlehnou. I moderní 
terapie založené na aktivaci imunitního systému nachází své hranice u mnohých typů 
nádorů. Rezistence vůči léčbě je zprostředkována nejen nádorovými buňkami, ale i jinými 
komponenty nádorového mikroprostředí. Porozumění mechanizmům nádorové rezistence 
zprostředkované nádorovými buňkami, ale i nádorovému mikroprostředí umožní vývoj 
nových terapeutických přístupů. 
 V této práci představujeme naše nedávné výsledky. Ozařování, 5-azacytidin i IFNγ 
indukují expresi genu suprabasin (SBSN) a vznik fenotypu nádorových buněk, který je 
zodpovědný za resistenci vůči terapii a projevuje se nízkou adhezivitou a kmenovými 
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vlastnostmi nádorových buněk. Snížení exprese genu SBSN vedlo k potlačení tohoto 
fenotypu. Rovněž jsme identifikovali aberantně zvýšenou expresi genu SBSN v kostní 
dřeni podskupiny pacientů trpících myelodysplastickými syndromy (MDS). Exprese SBSN 
byla zprostředkována supresorovými buňkami odvozenými z myeloidní řady (MDSCs)  
a hladina SBSN negativně korelovala se zastoupením T buněk a koncentrací CCL2 v 
kostní dřeni pacientů. Z toho vychází možný prognostický potenciál SBSN u MDS. V této 
práci shrnujeme nejdůležitější poznatky o SBSN spolu s našimi výsledky. Data zde 
prezentovaná ukazují na významnou roli onkogenu SBSN v nádorové rezistenci a jeho 

















2. Introduction  
2.1 Cancer  
Cancer is the second leading cause of death worldwide (Roth et al., 2018). Cancer is 
characterized as an aberrant growth of cells resulting in damage of surrounding tissue or 
dysfunction of an organ resulting in death of an individual.  
The current understanding of cancer seems to be relatively vast. Certain parts of 
carcinogenesis in adults are well described, whereas others are lacking. For example, novel 
mechanisms of oncogenic signalling, cancer resistance or tumour cells spreading are being 
described almost daily. Yet we do not have answers for the most important questions: why 
cancer starts and can it be ended?  
Certainly, environmental effects and lifestyle factors, such as unhealthy diet, 
smoking, or alcohol are associated with carcinogenesis, but we can ask why do individuals 
use these damaging substances? Oncoviruses promote tumorigenesis, hence are responsible 
for several tumour types (Mui et al., 2017) and, in some cases, for subsequent spreading 
(Bishop et al., 2012; Perri et al., 2018). Besides these, the origin of most cancer types (not 
the most prevalent cancer types) is considered as ‘bad luck’. A random mutation promotes 
dysregulated growth of cells and accumulation of other mutations, thus resulting in  
a tumour mass disrupting the function of tissues. Eventually, tumour cells’ spreading 
promotes growth at secondary sites, growing into overt metastases destroying affected 
organs. But the somatic mutation theory has its weak spots.  
A single mutation resulting in dysregulated growth would have to overcome the 
function of complementary allele, senescence, and immune surveillance. Therefore, 
mutations are rather a feature of cancer, a symptom of the disease. Cells adapt to changing 
environment without increasing the mutational burden (Pisco et al., 2013). This may result 
in dysregulated growth, which is subsequently responsible for increase in the mutational 
burden. Chronic inflammation promotes DNA damage, if unrepaired the accumulation of 
mutations is inevitable (Coussens and Werb, 2002). Immune surveillance, the essential 
feature of immune system, mediates clearance of malignant cells before the tumour mass is 
established (Swann and Smyth, 2007). However, if the immune system is suppressed via 
chronic inflammation, diet, drugs, emotional imbalance and stress, or separation  
(Friedman et al., 2003; Greten and Grivennikov, 2019; Kiecolt-Glaser and Glaser, 1995; 
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O’Leary, 1990; Seitz and Stickel, 2007), then immune surveillance may be disrupted. 
Therefore, understanding the complex nature of cancer is essential.  
 
2.2 Cancer death rates  
In 2019 ~10 million people died worldwide from cancer, it was 5.6 million in 1990, and is 
predicted to be ~13 million in 2030 (Ferlay et al., 2019; Roser and Ritchie, 2015). 
Therefore, age of cancer is yet to come, but cancer therapy faces the same challenges as 
ever before.  
A parameter of cancer prognosis, the overall 5-year survival, has increased from 50.3 
to 67% in the last 50 years, and cancer death rates (age-standardized cancer-caused deaths 
per 100.000 people in population) has declined by 15% over the last 30 years worldwide 
(Roser and Ritchie, 2015). It seems that cancer therapy has become more efficient, but this 
is not a correct interpretation. Both metrics are affected by several biases responsible for 
this seemingly positive progress. Besides others, the overall 5-year survival is affected by 
‘lead time bias’ and ‘overdiagnosis bias’ (Gigerenzer and Wegwarth, 2013). Better 
diagnostic tools allow earlier diagnosis or diagnosis of asymptomatic and possibly  
never-to-be symptomatic diseases. This results in the overall 5-year survival increase, yet 
patients die at similar age. In general, counts of cancer-caused deaths are affected by 
growing and aging population, therefore normalization to rates and age-standardization are 
required, hence the term ‘age-standardized cancer death rates’. In last 30 years, colon and 
stomach cancer showed decrease in cancer death rates (from 19.3 to 10.9 per 100.000 in 
case of stomach cancer and from 13.3 to 11.5 per 100.000 in case of colon cancer), but 
other 20 types of most prevalent cancer types has barely changed (these include lung, 
ovarian, brain, prostate and cervical cancer, etc.; Figure 1 and 2). Therefore, cancer death 
rates decrease in colon and stomach cancer is responsible for documented overall decrease 
in the metric. Better and earlier diagnosis is essential for decrease in cancer death rates in 
these two cancer types, which is certain in case of colon cancer (Roser and Ritchie, 2015). 
Still, surgical approach is the first-line option in both cases. Therefore cancer therapy has 





Figure 1. Worldwide cancer death rates in 1990 and 2017. Cancer death rates (age-normalized cancer 
caused deaths per 100.000 people) of twenty deadliest cancers worldwide in 1990 and 2017. Adapted from 









Figure 2. Central Europe cancer death rates in 1990 and 2017. Cancer death rates (age-normalized cancer 
caused deaths per 100.000 people) of twenty deadliest cancers in Central Europe in 1990 and 2017. Adapted 
from (Roser and Ritchie, 2015). 
  
2.3 Cancer therapies   
Following the surgical dissection, radiotherapy and chemotherapy remain the selected 
treatments for most tumours or unresectable types (Gilbert et al., 2013; Ledermann, 2018; 
Stupp et al., 2005; Tu and Hsu, 2018). For decades, chemotherapy agents, such as 
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methotrexate (Koźmiński et al., 2020), 5-azacytidine (Santini, 2019), or cisplatin  
(Dasari and Bernard Tchounwou, 2014) are still widely used. Certainly, novel approaches 
including immune-based therapies could not impact cancer death rates markedly just yet. 
Immune checkpoint inhibitors (ICI) have shown their use in melanoma  
(Herrscher and Robert, 2020; Zimmer et al., 2020). On the contrary, ICI as monotherapies 
did not provide satisfactory results in other cancer types (Huang et al., 2020)  
and resistances towards immunotherapies are already documented  
(Shah and Fry, 2019; Wylie et al., 2019). Thus, past failures represent future struggles.  
 
2.3.1 Radiotherapy  
The selection of therapy is based upon the stage of cancer and other criteria such as 
patients’ age. Patients with unresectable tumours are usually treated with radiotherapy or 
its combination with chemotherapy (Durante and Loeffler, 2010). Unresectable tumours 
are represented with, for instance, prostate cancer (treatment together with androgen 
deprivation therapy (Dal Pra et al., 2010)), unresectable bladder cancer, unresectable non-
small cell lung cancer (NSCLC) and many others (The Royal College of Radiologists, 
2019). 
Different radiotherapy setups and regimes are used. However, most commonly 
applied setups utilize 1.8 – 2 Gy per session over the course of 2 – 7 weeks. Therefore, the 
total dosage range is 20 – 70 Gy (Durante and Loeffler, 2010; The Royal College of 
Radiologists, 2019). 
Ionizing irradiation induces DNA damage that requires extensive repairs. This is 
promoted directly via irradiation, or via irradiation-induced free radicals (mostly reactive 
oxygen species; ROS) which also promote DNA damage. Most of the cells of tumour mass 
are considered to be highly proliferating due to high expression of oncogene(s). Therefore, 
quickly cycling cells are struggling with the repair. In mitosis, pro-apoptotic signals are 
promoted by damaged chromosomes and the cells eventually undergo cell death  
(Eriksson and Stigbrand, 2010). Extensive DNA damage may also promote p53-dependent 
apoptosis in interphase (Fridman and Lowe, 2003).  
Besides cancer cell death, radiotherapy also promotes senescence. Senescence is 
considered as primary tumourigenesis barrier as it certainly stops affected tumour cells 
from growth, however senescent cells are also associated with cancer resistance, growth, 
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and spreading. Hence induction of senescence with radiotherapy may represent a desired, 
but also unwanted effect (Tabasso et al., 2019). Importantly, other therapeutic approaches, 
such as genotoxic chemotherapies, also induced senescence in affected tumour cells 
(Venturelli et al., 2013). Therefore, targeting of senescent cells with senolytics, the 
senescent cell eliminating drugs, is proposed to be combined with cancer therapy  
(Demaria et al., 2017; Short et al., 2019).  
Therefore, irradiation-induced DNA damage results in cell death or senescence, 
thus suppressing the growth of malignant cells. This effect is also induced with many 
chemotherapeutic agents (Demaria et al., 2017; Short et al., 2019).   
 
2.3.2 Chemotherapy  
Chemotherapy includes large variety of small molecules which affect most of the cells in 
patients’ body. Various chemotherapeutic agents promote different effects, but eventually 
they all promote cell death via apoptotic pathway. Hence, apoptosis-avoiding mechanisms 
are often upregulated in tumour cells. Additionally, other mechanisms, such as export of 
the agents or their modification into inactive compounds are also utilized by tumour cells 
(Housman et al., 2014).  
 
2.3.2.1 5-azacytidine and 5-aza-2'-deoxycytidine  
5-azacytidine (5-AC; Vidaza
®
) (Šorm et al., 1964) and 5-aza-2'-deoxycytidine (5-dAC; 
Decitabine) (Pliml and Šorm, 1964) (Figure 3) were originally synthetized in 
Czechoslovakia in 1964. 5-AC represents an analogue of cytidine, whereas 5-dAC is an 
analogue of deoxycytidine. Both are hypomethylating agents, hence they promote 
reduction in methylation of DNA. Since DNA methylation is associated with silencing of 
genes, treatment with 5-AC or 5-dAC promotes changes in expression profiles of affected 
cells, but also other effects (Christman, 2002).  
5-AC incorporates into both, DNA and RNA. Incorporation into mRNA or tRNA 
affects translation. 5-AC promotes multiple effects, and this is likely dependent upon its 
concentration used, cellular uptake, efflux, and mechanisms responsible for its conversion. 
5-dAC incorporates into DNA only and this is likely responsible for its lower cytotoxicity. 
This also explains its higher efficiency in lower concentration (Christman, 2002). 
Therefore, the effect of 5-AC and 5-dAC in DNA is the same. Once incorporated into 
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DNA, both molecules may result in chromosome breakage. DNA methyltransferase 1 
(DNMT1) operates on cytosine residues in DNA, however, 5-AC or 5-dAC residues are 
also recognized. In an attempt to promote methylation of 5-AC or 5-dAC, DNMT1 
becomes irreversibly bound onto DNA. This results to loss of methylation, including CpGs 
islands of promoter sites, resulting in dysregulated expression of thousands of genes. In 
this manner, the manifestation of 5-AC or 5-dAC effect is dependent upon DNMT1 
abundance in a particular cell (Christman, 2002).  
Once DNMT1 reacts with 5-dAC incorporated in DNA, the DNMT1:5-dAC adduct 
is created. The adducts are ultimately responsible for the 5-dAC-induced cytotoxicity 
(Juttermann et al., 1994). These adducts promoted p53-mediated DNA damage response in 
colon tumour cells (Karpf et al., 2001), which is partially responsible for the 5-dAC-
mediated effect. Additionally, 5-dAC showed effect in vitro targeting human-derived 
tumour cells, when these cells showed prolonged cell cycle compared to treated fibroblasts 
(Bender et al., 1998). Similar results were achieved in vivo, when using a mice leukemic 
model (Covey and Zaharko, 1985).  
The repair of the DNMT1:5-AC adducts leads to degradation of DNMT1 and its 
interacting components of epigenome, including histones with repressive marks  
(Shen and Laird, 2013), this eventually enables the expression of downstream genes.  
Tumour cells show altered DNA methylation. It is recognized, that overall DNA 
methylation is reduced in tumour cells, but some genes are selectively hypermethylated, 
hence suppressed in expression (Costello et al., 2000). These include tumour suppressor 
genes (Sakai et al., 1991; Santini et al., 2001). Reactivation of tumour suppressor genes in 










Figure 3. Comparison of schemes of cytosine, 5-methyl-cystine, 5-azacytidine, and 5-aza-2´-
deoxycytidine. Both, cytosine and 5-methyl-cytosine represent diazines molecules, whereas 5-azacytidine 
and 5-aza-2´-deoxycytidine are triazines. As the names suggest, 5-azacytidine and 5-aza-2´-deoxycytidine 
contain nitrogen instead of carbon at position 5 of pyrimidine ring. Adapted from (Santini et al., 2001). 
 
Altogether, both 5-AC and 5-dAC mediate various effects. Which effects are 
induced depends on concentrations of the agent, or resistance mechanisms of the cells. 
However, the treatment may also lead to dysregulated expression of multiple genes, and 
their effect is hard to prognosticate. Importantly, the effect of 5-AC and 5-dAC in healthy 
fibroblasts is limited (Bender et al., 1998), hence providing a certain level of specificity 
towards malignant cells.   
 
2.3.3 Immunotherapy 
Immunotherapy brought new options with great potential into cancer treatment. The 
approach is predominantly based upon stimulation of immune response of the host through 
various treatments or techniques. These include adoptive T cell transfer  
(Humphries, 2013), vaccination via dendritic cells (Van Willigen et al., 2018), ICI 
(Pardoll, 2012), and several others. CAR-T cells recognizing specific antigens may also be 
included to this group (June et al., 2018). Similarly, the inhibitory antibodies may also be 
considered as an immunotherapy technique but their general mechanism of action differs.  
To promote efficient immune response which results in tumour cells elimination, 
antigen presentation by the tumour cells is crucial. Altered peptides of mutated genes 
(neoantigens) could be presented via antigen presentation mechanisms. Therefore, 
induction of neoantigen expression, or enhancement of this process, would promote 
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desired immune response (Wang and Cao, 2020). Additionally, expression of tissue-
restricted genes, such as cancer testis antigens (CTAs), towards which the central tolerance 
is not established (Suri et al., 2012), would also promote immune response. In order to 
achieve this effect, several agents promoting epigenetic changes were suggested as a co-
treatment with immune-based therapies. These include hypomethylating agents, such as 5-
AC or 5-dAC.  
Indeed, both 5-AC and 5-dAC induces expression of tissue-restricted genes, 
including CTAs (James et al., 2006; Karpf et al., 2004; Suri et al., 2012) e.g. NY-ESO-1, 
MAGE-A1, and master regulator of CTAs expression, BORIS (Karpf, 2006). Additionally, 
expression of silenced neoantigens could be elevated following 5-AC treatment; hence 
these antigens could be recognized with T cells as well (Wang and Cao, 2020). This would 
significantly help patients suffering from cancers that are associated with high mutational 
burden, such as melanomas (Chiappinelli et al., 2016). This has already been confirmed in 
mouse melanoma model (Chiappinelli et al., 2015), murine ovarian cancer models  
(Wang et al., 2015a) and murine pancreatic carcinoma models (Ebelt et al., 2020). 
Therefore, combination of immunotherapy with 5-AC was proposed.  
Immunotherapy holds a great promise, especially when combined with 
corroborating treatments which elevate immune response enhancing stimuli.   
 
2.4 Genotoxic stress 
Mutational burden is certainly a hallmark of cancer (Hanahan and Weinberg, 2011). 
Genotoxic stress may promote changes in genomic DNA sequence. Unresolved or wrongly 
repaired damage in DNA results in aberration. These mutations are propagated into 
daughter cells, thus altered genes are expressed. This results in aberrant phenotype. 
 Multiple mechanisms are responsible for genotoxicity. These are external, such as 
ionizing radiation or chemical agents (alkylating agents or intercalations agents), or 
intrinsic, such as reactive oxygen species (ROS) generated from cellular respiration or 
errors of replication (Coates et al., 2005). Inflammation also promotes DNA damage and 




 Highly proliferative cells, such as some cancerous cells, are indeed more sensitive 
to genotoxic stress. Additionally, mutations of DNA repair machinery genes  
(Fink et al., 1997) or their active silencing (Chen et al., 2010; Howard et al., 2009) are 
observed in cancer. This increases predispositions to other mutations to occur and leading 
eventually to cancer cell death. Hence genotoxic therapies provide reasonable solution.  
 Unfortunately, the mechanisms of resistance against radio- and chemo-therapy are 
being described. These include hypoxia of the tumour mass which provides radiotherapy 
resistance via reduced generation of double-strand breaks (Begg and Tavassoli, 2020). 
Hypoxia also promotes inflammation which enables immune evasion and spreading 
(Cummins et al., 2016). Similarly, multiple mechanisms enable chemotherapy resistance.  
  
2.5 Cancer resistance  
Cancer cells resistance remains the number one cause responsible for the therapy failure 
(Holohan et al., 2013). Secondly, tumour cells dissemination and subsequent growth at 
secondary sites are the predominant reasons why patients succumb to the disease (Klein, 
2011).  
Surgical resection of tumour mass does not guarantee complete elimination of 
every tumour cell, and in some cancer types or stages of progression, surgical resection  
is not an option; hence chemotherapy or other treatments are often applied. Despite the 
variety of therapies, all treatments must promote cell death of tumour cells. Therefore, cell 
death-evading mechanisms are upregulated in almost every cancer type. These include 
upregulation of anti-apoptotic genes (such as BCL-2 family of genes: BCL2, BCL-XL, or 
MCL1 (Kale et al., 2018)) and activation of pro-survival signalling pathways (e.g Akt or 
Erk pathways (Lu et al., 2020; Revathidevi and Munirajan, 2019)). Therefore, inhibiting 
these targets is of interest. Indeed, antagonists recognizing BCL-2 family proteins, such as 
Venetoclax, ABT-737, or S63845 are finding its way into clinics (Roberts et al., 2019; 
Yasuda et al., 2020). However, resistance toward these agents is already being described 
(Konopleva et al., 2006; Tausch et al., 2019). Similar is the case of inhibitors targeting pro-
surviving pathways as potential therapeutic agents (Jaiswal et al., 2018).  
Modify, and thus inhibiting chemotherapy agents, or their active efflux is also 
commonly utilized by tumour cells (Housman et al., 2014). ATP-binding cassette (ABC) 
genes represent transmembrane proteins encoding family of genes responsible for 
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chemotherapy resistance utilizing the drug efflux. Multi-drug resistance protein 1 (MDR1) 
is most well studied gene of the family, yet other 48 members are identified. It is proposed 
that upon inhibition different members of the family may take on the actions of the 
inhibited member (Szakács et al., 2004). Additionally, vincristine induced MDR1 
expression in a leukemic models via Wnt pathway activation (Pisco et al., 2013), hence 
adaptive non-mutational mechanisms participate in cancer resistance. Altogether, this 
likely explains failures of ABC inhibitors in clinical trials  
(Pusztai et al., 2005; Ruff et al., 2009).  
Upregulation of immune-evading mechanisms is also observed (Holohan et al., 
2013; Kalbasi and Ribas, 2020; Schoenfeld and Hellmann, 2020). This is responsible for 
evading the immune surveillance prior therapy, but also responsible for immunotherapy 
resistances. Overexpression of IFNγ receptors (Pan et al., 2018) and activation of IFNγ 
response in tumour cells promotes resistance via upregulation of CD274 (also known as 
programmed death-ligand 1; PD-L1) (Bellucci et al., 2015; Garcia-Diaz et al., 2017) or 
secretion of PD-L1-exposing exosomes (Chen et al., 2018). These mechanisms are 
partially responsible for observed resistance towards infiltrated T cells (Patel et al., 2017). 
Conversely, IFNγ also induces expression of genes encoding MHC I components (Basham 
and Merigan, 1983; Kalbasi and Ribas, 2020).  
Antigen presentation via MHC I is essential for T cell-induced cell death of tumour 
cells. However, mechanisms responsible for downregulation MHC I are described. Some 
tumour types showed silencing of MHC I genes (Restifo et al., 1996; Sucker et al., 2014). 
The mediators of IFNγ signalling, JAK1 and JAK2 were documented to be inactivated by 
mutation in melanoma patients (Zaretsky et al., 2016), and STAT1 was shown to be 
suppressed in mouse model (Benci et al., 2016). Additionally, hyperactivation of Erk 
pathway (Frederick et al., 2013), which is often mediated by activating mutation of the 
components of the pathway, was also shown to repress MHC I expression. All marking 
evolution of mutant clones.  
Similar to radiotherapy or chemotherapy, IFNγ signalling also induces DNA 
damage and cellular senescence. This is mediated via ROS generation and induction of 
TGFꞵ (Braumüller et al., 2013; Hubackova et al., 2015). Hence immune editing may also 
induce genotoxic stress, which results in inhibition of proliferation. 
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Besides suppression of antigen presentation, Erk pathway induced expression of 
IL6, IL10, and VEGF paralogues (Sumimoto et al., 2006). These signalling molecules 
represent essential stimuli promoting immunosuppression and stimulation of 
dissemination. Next, Wnt pathway promoted IL10 expression in melanoma as well 
(Yaguchi et al., 2012), and activation of Wnt in dendritic cells dampened their anti-
tumorigenic function (Spranger et al., 2015). Furthermore, infiltration of T cells negatively 
correlated with Wnt pathway activation in colorectal cancer and ovarian cancer (Grasso et 
al., 2018; Jiménez-Sánchez et al., 2017). And ꞵ-catenin marked stemness of cancer cells in 
several tumour types (Malanchi et al., 2012; Vermeulen et al., 2010; Wang et al., 2015b). 
In general, cancer stem cells (CSCs) are therapy-resistant cells with tumour growth-
initiating potential responsible for secondary site metastases.   
Altogether, combination of therapeutic approaches including inhibitors of Erk or 
Wnt pathway together with immunotherapy are currently ongoing or reported (Ascierto et 
al., 2019; Ebert et al., 2016; Ribas et al., 2019) and showing promising response rates. 
However, tumour cells are not the only compartment responsible for immune suppression. 
Novel immune-based therapy approaches must face additional complications, which are 
promoted via suppressive cells of the tumour microenvironment (TME) (e.g. anti-
inflammatory macrophages (also known as M2 macrophages) or myeloid-derived 
suppressor cells, MDSCs) (Nakamura and Smyth, 2020).  
 
2.6 Tumour microenvironment  
Besides tumour cells, the tumour mass is composed of various cells types. These include 
the cells of the tissue affected by malignant conditions, cancer-associated fibroblasts, 
endothelial cells, and senescent cells, but also cells of the immune system.  
Later group is consisted of anti-tumour and pro-tumour cells. Anti-tumour cells are 
represented by cytotoxic T lymphocytes, anti-tumour macrophages, dendritic cells, and 
natural killer (NK) cells. Pro-tumour cells are represented by anti-inflammatory 
macrophages, regulatory T cells (Tregs), and MDSCs. All these components create TME. 
In some cases, extracellular matrix (ECM) and nerves are also considered to be 
components of TME (Gabrilovich et al., 2012; Vitale et al., 2019; Whiteside, 2008; 
Zahalka and Frenette, 2020). 
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TME mediates a complex network of interaction, metabolites transfer, and signals, 
altogether enabling tumour growth, evolution, resistance, and spreading  
(Greten and Grivennikov, 2019). Inflammatory signalling represent a dominant feature of 
TME associated with its aforementioned properties. These include innate immune signals, 
such as alarmins, damage-associated molecular patterns (DAMPs), and also pathogen-
associated molecular patterns (PAMPs). But also inflammatory cytokines of varying 
nature, such as IL-1ꞵ, IL-6, IL-10, TGFꞵ, TNFα and many others (Medzhitov, 2008). 
Despite certain effort, in most cases, the initial source of inflammation is not known. 
Infection, autoimmune response, or systemic chronic inflammations induced by other 
malignancies are often on the onset of tumourigenesis and related inflammation 
(Grivennikov et al., 2010). Note, therapy may also potentiate inflammatory conditions 
(Greten and Grivennikov, 2019). And inflammatory milieu promotes epigenetic changes 
similar to changes induced with activity of oncogenes (Schwitalla et al., 2013), hence 
accumulation of mutations is enabled.  
Pro-inflammatory signals derived from TME stimulate anti-inflammatory response; 
however, the immune system is only partially responsible for the expression of pro-
inflammatory stimuli (Greten and Grivennikov, 2019). The other components of TME, 
such as tumour cells, cancer-associated fibroblasts, and senescent cells are also responsible 
for secretion of pro-inflammatory molecules. Inflammatory signalling enhances stemness 
of the tumour mass (Francart et al., 2018), and its therapy resistance. These cells, however, 
are not the targets of anti-inflammatory response mediated by anti-inflammatory 
macrophages, MDSCs, and other cell types, which efficiently suppress cytotoxic cells with 
anti-tumour activities; hence the pro-tumour milieu is established  
(Gabrilovich et al., 2012).  
The malignant growth of the tumour mass is also associated with reduced oxygen 
availability; hence multiple signals stimulate neovascularization of TME. HIF-1A 
stabilization is also associated with cancer stemness, and cancer stem cells possess tumour 
growth-reinitiating potential at primary or secondary sites (Chen et al., 2020). Formation of 
novel blood vessels allows tumour growth and dissemination.  
 Despite being commonly described as a feature of solid tumours, haematological 
diseases, such as leukaemia and lymphomas also possess TME (Höpken and Rehm, 2019). 
Certainly, aspects of these TME deviate from TME of solid tumours, but the cellular 
composition is similar. In recent years, MDSCs in the bone marrow of myelodysplastic 
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syndromes (MDS) patients, the pre-leukemic diseases, were proposed to promote immune 
evasion, but were also shown to promote erythropenia and to establish inflammatory 
milieu in the bone marrow of MDS patients (Chen et al., 2013). Therefore, MDSCs are 
also responsible for the features of the disease itself.  
 
2.7 Tumour dissemination  
Dissemination of tumour cells from the primary sites may result in growth at secondary 
sites, usually distant organs with certain degree of specificity for some cancer types (e.g. 
prostate carcinoma and bone metastases, sarcomas and lung metastases), but mostly affects 
sites with smaller capillaries, such as liver, brain, lungs, and bone marrow  
(Carbonell et al., 2009; Szmulewitz et al., 2015). The process of dissemination may occur 
throughout the course of tumourigenesis (Brastianos et al., 2015; Hüsemann et al., 2008; 
Klein, 2011). Some reports suggest that therapy may facilitate this process as well  
(Greten and Grivennikov, 2019). Loss of adhesion to surrounding cells and matrix, 
migration of the cells, entering lymphatics or bloodstream, and subsequently leaving the 
bloodstream, are events necessary prior the growth of disseminated cancer cells. These 
processes require phenotypic changes in primary tumour cells (Dongre and Weinberg, 
2019; Williams et al., 2019).  
Cancer cells exploit multiple states which may ultimately result in cancer 
dissemination. The epithelial-mesenchymal transition (EMT) represents a range of 
phenotypes associated with invasiveness of tumour cells. Importantly, EMT is promoted 
via malignant milieu of TME, and some of the stimuli are also provided by tumour cells 
themselves (Giannoni et al., 2010; Jing et al., 2011; Radisky et al., 2005; Williams et al., 
2019). This includes signalling molecules, such as TGFꞵ (Xu et al., 2009), WNTs 
(Teeuwssen and Fodde, 2019), IL-6 (Ebbing et al., 2019), and mitogenic factors  
(Kim et al., 2016), as well as cell-to-cell contact-induced signalling via NOTCHs 
(Natsuizaka et al., 2017). 
The signals of TME then induce expression of EMT master regulators: SNAI1, 
SNAI2, TWIST1, TWIST2, ZEB1, and ZEB2. These transcription factors orchestrate 
epigenetic changes and expression of thousands of genes responsible for suppression of 
epithelial phenotype, active remodelling of the surrounding matrix, and promotion of 
mesenchymal phenotype. These changes elevate invasiveness of the cells. Once leaving the 
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original milieu of primary tumour site, the migrating cells may spread into the distant 
organs, the secondary sites. There, the stimuli responsible for EMT are lost, thus the 
reverse process, the mesenchymal-epithelial transition (MET) occurs. State of cellular 
dormancy follows, but upon its exit, the out-migrated cells re-enter the cell cycle and 
promote growth of micrometastases; cancer cell microcolonies at the distant sites 
potentially initiating cancer growth upon escaping dormancy  
(Dongre and Weinberg, 2019).  
Besides EMT, several other types of invasive phenotype were described. Cancer 
cells were shown to migrate collectively (Cheung et al., 2016). In this case, only some of 
the cells showed mesenchymal phenotype, whereas other cells of the migrating cluster 
showed rather epithelial phenotype (Cheung and Ewald, 2016; Cheung et al., 2016).  
Other types of migratory phenotypes are dependent upon interaction with neuron cells, 
which serve as a path of migration (Magnon et al., 2013). Stress conditions, such as 
hypoxia, may induce another transition from mesenchymal phenotype into amoeboid, so 
called the mesenchymal-to-amoeboid transition (MAT) (Lämmermann and Sixt, 2009; 
Lehmann et al., 2017). It is proposed, that the invasiveness of cancer cells with the 
amoeboid phenotype is not dependent upon remodelling of extracellular matrix. But the 
precise nature of this phenomenon is yet to be determined in vivo  
(Lämmermann and Sixt, 2009; Lehmann et al., 2017; Sabeh et al., 2009).  
Nevertheless, the migratory phenotypes are commonly associated with expression 
of stem cell markers, such as SOX2 or CD44 (Al-Hajj et al., 2003; Alonso et al., 2011; 
Giannoni et al., 2010; Prince et al., 2007; Thiery et al., 2009; Vlashi and Pajonk, 2015). 
Most of the disseminated cells are likely tumour-initiating CSCs, or the migrating cells 
enter the state of stemness, thus become CSCs or cancer stem-like cells. The migrating 
cells represents non-cycling cells, thus some therapeutic approaches do not affect these 
subtypes. Additionally, autophagy is associated with CSCs and their therapy-resistance 
(Amaravadi et al., 2007; Lu et al., 2008; Nazio et al., 2019; Sosa et al., 2014). Altogether, 
disseminated tumour cells represent invasive and highly therapy-resistant subtype of 
tumour cells.  
Additionally, disseminated tumour cells require a suitable niche for their growth. 
Multiple conditions, such as stemness, specific expression profiles, and senescent cell 
composition of the niche were suggested as important factors for efficient dissemination 
(Kaplan et al., 2005; del Pozo Martin et al., 2015). Additional factors are being evaluated. 
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This indicates that different conditions are needed for different tumour cells for efficient 
dissemination. Furthermore, both disseminated tumour cells and tumour cells at primary 
site provide stimuli which may regulate efficacy of the dissemination process as well 
(Hoshino et al., 2015).  
 
2.8 Cancer recurrence  
The therapy-surviving tumour cells or their subpopulations may promote tumour 
recurrence at the primary site. Furthermore, dissemination and metastatic diseases are also 
troublesome. Metastatic cells are highly invasive and therapy-resistant; they promote 
growth of micrometastases. However, the disseminated cells must undergo multiple 
complex, and thus hard to predict events, which may lead to overt metastases to occur 
years after initial diagnosis (Pan et al., 2017). Exposing mechanisms responsible for the 
switch of phenotype of metastatic cells would allow development of novel therapeutic 
strategies. Similarly, genes essential in these processes would enable better understanding 
of the events. Novel models of metastatic diseases are needed, since observations of the 
dissemination processes are highly stochastic in vivo. Additionally, therapy treatments 
potentiate the dissemination process (Anderson and Dische, 1981; von Essen, 1991; Martin 
et al., 2014; Moncharmont et al., 2014; Yuan et al., 2015); hence elucidating therapy-
promoted changes in tumour cells and TME is of great importance.  
 
2.9 Cancer dormancy  
Metastatic disease may occur years after the diagnosis or treatment of the tumour. This is 
due to dormancy of tumour cells at secondary sites. Dormancy represents a highly resistant 
reversible non-cycling state of cells. The causes for cancer dormancy are still elusive.  
In part, dormancy represents a feature of cancerous cells. However, dormant 
cancerous cells must overcome several issues associated with novel environment to 
promote the growth of micrometastases. Therefore, stimuli of pre-metastatic niche play 
crucial roles in exiting the state of dormancy (Bartkowiak et al., 2010; Hüsemann et al., 
2008; Shiozawa et al., 2008; Sosa et al., 2014). The nutrients and oxygen supply must be 
provided to exit the dormant state of cancerous cells  
(Aguirre-Ghiso, 2007; Holmgren et al., 1995) Additionally, the dormant cells must 
overcome the immune editing (MacKie et al., 2003). The same is required for 
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micrometastases to grow into overt metastases. The immune editing is likely the main 
reason for late metastatic growth (MacKie et al., 2003), once the immune response is 
suppressed, the metastases may grow uncontrolled  
(Jimsheleishvili et al., 2014; Strauss and Thomas, 2010). 
Three types of dormancy are defined: cellular, angiogenic and immune-induced 
dormancy (Aguirre-Ghiso, 2007). Cellular dormancy, an intrinsic program of the 
disseminated tumour cells, is sustained via multiple pathways. Additionally, this state is 
also regulated by outer stimuli provided by the environment. These include activation of 
p38 and Erk pathway in a ratio favourable for p38 pathway (Bartkowiak et al., 2010; 
Kobayashi et al., 2011; Masiero et al., 2011) (BMP7 mediated this effect via induction of 
p38 and via upregulation of p21 and p27 (Kobayashi et al., 2011)), suppression of Akt 
activity (Balz et al., 2012; Marshall et al., 2012), and activation of stress response in form 
of unfolded protein response (UPR) (Bartkowiak et al., 2010). Similarly to EMT, the 
dormant cancer cells are highly resistant to chemotherapy (Bartkowiak et al., 2009). This is 
likely mediated by stress response promoting autophagy, which is associated with therapy 
resistance (Lu et al., 2008; Sosa et al., 2014). CSCs also show elevated expression of ABC 
genes, responsible for drug efflux (Shervington and Lu, 2008). Additionally, the dormancy 
is also accompanied with the expression of stemness and quiescence factors  
(Adam et al., 2009). TGFꞵ2 signalling represents an additional stimulus for cancer 
dormancy (Bragado et al., 2013; Yumoto et al., 2016), but TGFꞵ3 and POSTN signalling 
were shown to awaken the dormant cells, thus promoting cell cycle entrance  
(Ghajar et al., 2013; Malanchi et al., 2012).  
Causes for exit from cellular dormancy are not entirely clear. Once again, the 
environment certainly plays an important role, since TGFꞵ3 and POSTN signalling 
induced by endothelial cells of vascular vessels promoted proliferation in the dormant cells 
(Ghajar et al., 2013; Malanchi et al., 2012). The entrance of the dormant cells into cell 
cycle is also accompanied with increased expression of VCAM1 (Lu et al., 2011) and 
activation of MYCK (Barkan et al., 2008). Why and how are these events induced is not 
elucidated, however, it was hypothesized that the dormant cells must overcome angiogenic 
dormancy prior to overcoming cellular dormancy (Sosa et al., 2014). Some speculate that 
therapy might promote genetic or epigenetic changes required for exit of cellular dormancy 
state (Goddard et al., 2018).   
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Theoretically, onset of immune system-mediated regulation of cancer dormancy 
follows angiogenic and cellular dormancy escape. After these events, proliferating 
disseminated cancer cells promote micrometastatic growth, whereas cytotoxic cells of the 
immune systems may eliminate disseminated cancerous cells, or equilibrium between 
cancer cell growth and cancer cell death is established. The cells of the immune system, 
predominantly CD8+ cytotoxic T lymphocytes and NK cells, are responsible for these 
events via IFNγ secretion and signalling. IFNγ induces G0 arrest in dormant cells via p27 
(Farrar et al., 1999; Liu et al., 2017). Alternatively, CD4+ lymphocyte-mediated secretion 
of anti-angiogenic factors, CXCL9 and CXCL10, suppresses angiogenic events in the 
milieu (Müller-Hermelink et al., 2008).  
The dormant cancer cells must overcome the immune surveillance to disrupt the 
equilibrium and establish an environment enabling their growth. Primary tumour mass, 
tumour cells, and associated non-cancerous cells of TME utilize multiple mechanisms 
responsible for evasion of the immune surveillance. However, mechanisms responsible for 
the immune evasion at secondary sites are described poorly. Cell lines derived from the 
dormant cells showed elevated expression of MHC I complexes (Mahnke et al., 2005), 
which allows evasion of NK cells-induced cell death, but not CD8+ lymphocytes induced-
cell death. We can speculate that the disseminated tumour cells carry some of the genomic 
and epigenetic changes from primary tumour cells, which would allow CD8+ induced-cell 
death evasion or resistance, but these notions require further investigation.  
Certainly, understanding the mechanisms of all types of dormancies is challenging, 
but necessary to eliminate the dormant cancer cells in patients. Several clinical trials have 
applied preventive treatment following primary tumour eradication, to eliminate or inhibit 
the growth of the dormant cancer cells (ClinicalTrials.gov identifiers: NCT03032406, 
NCT03400254, NCT01545648). Interestingly, one trial already showed markedly 
increased metastatic-free survival period, utilizing docetaxel following chemotherapy in 
breast cancer patients (Naume et al., 2014). These results indicate that dormancy must be 
counted with. A deeper understanding is crucial and will likely be beneficial.  
 
2.10 Myeloid-derived suppressor cells  
Among various immune suppressive cells of TME, MDSCs represent a very special 
compartment. MDSCs are relatively recently identified cells with a strong immune 
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suppressive capacity targeting predominantly T lymphocytes and NK cells. MDSCs 
promote tissue remodelling and neovascularisation, both processes associated with the 
tumour dissemination. Additionally, their abundance in patients’ peripheral blood 
correlates with worsen prognosis and reduced therapy efficacy (Chen et al., 2014; Ostrand-
Rosenberg and Fenselau, 2018). 
Myelopoiesis-stimulating factors (e.g. GM-CSF, G-CSF, M-CSF) derived from the 
tumour mass stimulate expansion of myeloid precursors in the bone marrow (Bronte et al., 
1999; Dolcetti et al., 2009). Subsequently, the myeloid precursors are targeted with pro-
inflammatory stimuli derived from TME (Figure 4) (Bronte et al., 1999; Condamine et al., 
2015; Dolcetti et al., 2009). This initiates immune-suppressive programs of expanded 
myeloid precursors, thus deriving MDSCs. MDSCs then migrate to the source of the pro-
inflammatory stimuli, TME, to suppress these conditions. However, MDSCs suppress only 
the infiltrated lymphocytes and NK cells, but not the other sources of pro-inflammatory 
stimuli, thus the malignant milieu is reinforced and immune evasion is enabled 
















Figure 4. A scheme of stimulation of myeloid-derived suppressor cells (MDSCs). Myelopoiesis-
stimulating factors are released from the tumour mass (e.g. GM-CSF, G-CSF, M-CSF, and VEGFs) and 
travel into the bone marrow. Expanded myeloid precursors are released from the bone marrow and stimulated 
with pro-inflammatory stimuli (e.g. DAMPs, PAMPs, HMGB1, ILs, PGE2, VEGFs). Subsequently, their 
immune suppressive program is initiated, hence MDSCs are derived. MDSCs then migrate into the tumour 
mass and inhibit the immune surveillance. CSF – colony stimulating factor, GM – granulocytes/monocytes, 
G – granulocytes, M – macrophages, VEGF – vascular endothelial growth factor, DAMPs – damage-
associated molecular patterns, PAMPs –  pathogens-associated molecular patterns, HMGB1 - high mobility 
group box 1, ILs – interleukins, PGE2 – prostaglandin E2. Adapted from (Pribyl, 2020). 
 
In total, three subtypes of MDSCs are described. These are: polymorphonuclear 
MDSCs (PMN-MDSCs: morphologically resembling granulocytic myeloid cells, such as 
neutrophils), monocytic MDSCs (MN-MDSCs: resembling monocytes), and early-stage 
MDSCs (eMDSCs: resembling blast cells, monocytes, but also granulocytes). In human, 
MDSCs identification is relatively complicated. Usually, staining of surface markers is 
utilized (Bronte et al., 2016). In case of PMN-MDSCs, the staining of surface markers does 
not distinguish PMN-MDSCs from neutrophils. Therefore, ficoll gradient isolation is 
required. Following the procedure, the mononuclear fraction (the low-density fraction) 
contains PMN-MDSCs, whereas neutrophils are in the high-density fraction. However, this 
does not distinguish PMN-MDSCs from activated neutrophils. Such observations support  
a notion that PMN-MDSCs represent immune suppressive state of activated neutrophils 
(Pillay et al., 2013; Sippel et al., 2011), yet this needs further elucidation.  
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The immune suppressive capacity of MDSCs is mediated via multiple mechanisms 
from two main categories. These are: T cell receptor (TCR)-dependent and TCR-
independent. This is based upon mechanisms of action. TCR-dependent mechanisms 
inhibit the function of TCR directly, thus reducing its antigen-recognizing potential. This is 
mediated via reaction of TCR with MDSCs-synthetized peroxynitrite (ONOO−)  
(Nagaraj et al., 2007). Additionally, peroxynitrite efficiently nitrates CCL2 chemokine. 
Nitrilated CCL2 is not recognized by its original recipients, monocytes and T cells, but is 
an efficient chemokine of MDSCs (Molon et al., 2011).  
TCR-independent mechanisms include secretion of cytokines (Gabrilovich et al., 
2012; Sinha et al., 2007), such as IL-10 which polarizes macrophages into suppressive M2 
phenotype. Reduction of cysteine and tryptophan availability in the milieu strongly affects 
the function of T cells. This is mediated via cytosine import and extracellular catabolism of 
tryptophan and arginine with IDO-1, or Arg-1 respectively (Rodriguez et al., 2004; 
Srivastava et al., 2010). Production of ROS is also utilized by MDSCs. Their actions 
promote reduction of TCR expression, hence T cell ability to recognize antigens is 
diminished (Corzo et al., 2009).  
Additionally, MDSCs utilize cell-to-cell interaction to promote anergy in T cells. 
This is mediated mainly via PD-L1 induced actions (Iwata et al., 2016). MDSCs may also 
induce CD62L cleavage on the surface of T cells with ADAM17 protease, thus regulating 
ability of T cells to migrate into lymph nodes (Hanson et al., 2009). 
Besides immune cells suppression, physiological function of MDSCs also lies in 
their ability to enhance the repair of damaged tissues. Extracellular matrix remodelling and 
induction of neovascularisations are two main features associated with tissue repair 
promoted by MDSCs. Secretion of matrix metalloproteinases and pro-angiogenic factors 
such as VEGFs promote these processes, but may be hijacked by tumour cells to promote 
their growth and spreading, which has been documented (Binsfeld et al., 2016; Johnson et 
al., 2018; Sinha et al., 2005; Yang et al., 2004).  
Since MDSCs must pass from the peripheral blood into TME and their generation 
is directly regulated via tumour mass-secreted signals, their presence in the peripheral 
blood reflects the stage of progression. Indeed, breast carcinoma (Diaz-Montero et al., 
2009), esophageal carcinoma (Chen et al., 2014), and thyroid cancer patients (Angell et al., 
2016) showed elevated MDSCs level with the stage of progression. The overall survival of 
32 
 
melanoma patients was markedly reduced with elevated MDSCs peripheral blood levels 
(Jordan et al., 2013). MN-MDSCs specifically marked reduced survival rates in 
lymphomas (Marini et al., 2016; Wu et al., 2015) and multiple myeloma (Wang et al., 
2015c). MN-MDSCs also markedly reduce chemotherapy efficacy in multiple myeloma 
(Lee et al., 2016) and Hodgkin’s lymphoma (Romano et al., 2015). Additionally, elevated 
MDSCs levels predicted lower efficacy of ipilimumab in melanoma (Sade-Feldman et al., 
2016) and MN-MDSCs marked the reduction of nivolumab efficacy also in melanoma 
(Weber et al., 2016).  
Certainly, MDSCs represent detrimental components of TME responsible for its 
main features. In MDS, eMDSCs were shown to promote cell death of erythroid 
precursors, and thus promote pathological features of the disease (Chen et al., 2013). 
Therefore, eliminating MDSCs in MDS could alleviate from this symptom.  
Altogether, MDSCs promote immune evasion, growth of tumour cells and facilitate 
their spreading. Targeting MDSCs with therapy has been proposed but results of several 
clinical trials attempting to eradicate MDSCs from TME are not satisfying (Winter et al., 
2020). Furthermore, sole elimination of MDSCs does not prevent from their further 
accumulation, thus combination with elimination of other components of TME could 
provide more satisfying outcomes. 
 
2.11 Myelodysplastic syndromes 
A heterogeneous group of pre-leukemic diseases is known as myelodysplastic syndromes 
(MDS). Pro-inflammatory conditions in the bone marrow of MDS patients are established 
resulting in failure of the compartment (Sallman and List, 2019; Winter et al., 2020). 
Mutant clones of haematopoietic stem cells and progenitors (HSPCs) of myeloid lineage, 
so called blasts, thrive under inflammatory conditions (Muto et al., 2020). In general, blasts 
are recognized as non-differentiating cells of myeloid lineage, hence myeloid lineage of 
patients is strongly affected. Therefore, neutropenia, anaemia, and thrombocytopenia are 
common symptoms associated with the disease, and also main life-threatening aspects of 
the disease. Despite certain effort, blast mutations commonly associated with MDS 
struggle to make their way into clinics (Haferlach et al., 2014; Hasserjian, 2019). Blasts 
abundance in the bone marrow and cytogenetic profile of blasts are diagnostic criteria most 
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commonly utilized nowadays (Arber et al., 2016; Greenberg et al., 1997a; Winter et al., 
2020).  
Multiple criteria are used as diagnostic parameters. These include neutrophils 
count, haemoglobin concentration, and thrombocytes count, all measured in the peripheral 
blood of the patients. Next, the bone marrow biopsies reveal the blast count, which is a 
crucial determinant of patients’ prognosis. And cytogenetic profile of the bone marrow 
cells is determined. Altogether, these numbers and the cytogenetic profile determine the 
prognostic score based upon which the patients are assigned into prognostic groups. With 
several updates, the most commonly used prognostic scoring systems are: Revised 
International Prognostic Scoring System (IPSS-R) (Greenberg et al., 2012) and World 
Health Organisation (WHO) classification (Arber et al., 2016). Nevertheless, which system 
is used is dependent upon clinicians; hence 1997 IPSS is sometimes also used (Greenberg 
et al., 1997b), despite its update in 2012. The patients corresponding to the low-risk groups 
are monitored or receive blood transfusions if necessary. The high-risk group patients 
receive chemotherapy, 5-azacytidine or 5-aza-2'-deoxycytidine. This has not changed for 
last 20 years, since no better treatment has passed clinical trials. The only exception is 
lenalidomide, which is utilized for MDS 5q- syndrome patients (Krönke et al., 2015). 
Usually, this group of patients has better prognosis. 
Together with blasts’ accumulation, the bone marrow milieu changes  
(Barreyro et al., 2018; Sallman and List, 2019; Winter et al., 2020). Repercussions of these 
changes may eventually lead to leukemic transformation, most commonly into acute 
myeloid leukaemia (AML) or chronic myelomonocytic leukaemia (CMML). In clinics, 
AML is considered when patients’ bone marrow blasts reaches >20% or >25%, hence 
definition of AML differs according to the prognostic score applied. MDS median survival 
varies according to patients corresponding prognostic group. The low-risk group has 5.7 
years median survival, the high-risk group have 5 months median survival according to 
IPSS (Greenberg et al., 1997a). Additionally, 25% of patients transform into AML. In 
elderly AML patients, median survival is 6 months when chemotherapy is utilized. 
Without chemotherapy, AML median survival is 2 months (Oran and Weisdorf, 2012). If 
haematopoietic stem cells transplantation is an option, the survival is usually extended by 
several months, in the high-risk MDS (Beran, 2000) and AML (Oran and Weisdorf, 2012). 




2.11.1 5-azacytidine and 5-aza-2'-deoxycytidine in MDS and AML 
5-AC and 5-dAC were used in various clinical trials. However, for the purpose of this 
introduction; we refer to studies which we consider to be related to the topic of this thesis.  
Several clinical trials applied 5-AC as a monotherapy in MDS. These trials applied 
varying dosing of 5-AC: 75 mg/m
2
 daily for 7 days (Silverman et al., 1993) with 12% 
complete remission, 25% partial remission. In a subsequent study the high-risk MDS 
patients received 5-AC, 75 mg/m
2
 seven times daily every 4 weeks (99 patients), versus 
non-treated patients (92 patients) in 191 patients with the high-risk MDS. In this trial, 6% 
complete remission was achieved, 10% partial remission, 47% haematological 
improvement  (Silverman et al., 2002). Median for leukemic transformation was 22 months 
vs. 12 months, and median survival 18 months vs. 14 months. These studies contributed 
most significantly in application of 5-AC as a first-line treatment for MDS  
(Kaminskas, 2005).  
Alterations in 5-AC dosing applying 40 to 50 mg/m
2
 given over 24 hours for three 
days every 6 weeks (Wijermans et al., 1997) and later with 15 mg/m
2
 given over 4 hours 
every 8 hours for 3 days every 6 weeks (Wijermans et al., 2000) (in both cases, the total 
dose was 120 to 150 mg/m
2
 per course). The response rates were similar for the trials 
reaching 50% response rate. Newer studies correspond to these pioneering results (Santini, 
2019). In the next trial, 20% of patients showed complete remission and a median survival 
reached 19 months in Int-1 group vs. 15 months control group. This was not achieved in 
the high-risk groups (Wijermans et al., 2000). 
Haematopoietic stem cells transplantation is the only curative option for eligible 
MDS patients, with three-years relapse free survival in 24% of MDS patients  
(Festuccia et al., 2017). This is reduced in patients with TP53, ASXL1, or RUNX1 mutation 
(Della Porta et al., 2016). Patients with TP53 mutation showed 30% relapse-free survival 
in one-year period and only 10% in 3-year period (Della Porta et al., 2016).  
5-dAC induced expression of immune checkpoint ligands by CD34+ blasts from 
MDS and AML patients (Øyan et al., 2005) and the high-risk MDS possessed higher levels 
of CTLA-4, PD-L1, and PD-L2. The expressions of these genes were elevated with 5-dAC 
treatment (Yang et al., 2014). Relatively high immune checkpoint expression is likely 
responsible for CD8+ T cells exhaustion in high-risk MDS patients. Hence, T cells of these 
patients could be more prone to ICI therapy. However, single therapy ICI showed low 
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efficacy in AML and MDS patients (Garcia-Manero et al., 2016), but anti-CTLA-4 showed 
effect in 5-dAC treated refractory MDS patients (Garcia-Manero et al., 2016). Therefore, 
combination of ICI with 5-dAC is of interest (Daver et al., 2018). Yet deeper 
understanding of the bone marrow milieu of MDS is essential.  
 
2.11.2 The bone marrow of MDS  
Haematopoiesis takes place in the bone marrow, where HSCPs reside in stem niches. 
Vascular, reticular, and endosteal niches are responsible for regulation of HSCPs 
expansion, differentiation, and renewal, but also for retaining their quiescence. These 
effects are mediated via complex milieu of cytokines and other signalling molecules 
creating a strictly regulated yet responsive environment of the bone marrow  
(Ghobrial et al., 2018).  
Inflammation is a detrimental feature of ongoing MDS (Figure 5). However, the 
causes for aberrant milieu are not clearly elucidated. Similarly to the inflammatory 
response in solid tumours described in previous chapters, the inflammation could be 
initiated via autoimmune response, inflammaging, or stimulation of innate immune 
response induced with bacterial components (Braun and Fenaux, 2013; Sallman and List, 
2019), yet a clear evidence is missing. Despite being documented as important mediators 
of the bone marrow changes in MDS, mutations commonly associated with MDS play only 
partial role in these alterations. Mutations of splicing factors machinery may promote 
changes in blast gene expression enhancing the inflammatory response of malignant clones 
(Liang et al., 2018); however, mutations themselves might not be detrimental during the 




Figure 5. Progression of changes in the bone marrow of MDS. Chronic inflammation in the bone marrow 
is promoted by different sources. Mediators of inflammation are inflammatory molecules (DAMPs, 
ROS/RNS) and inflammatory cytokines (IL-6, IL-1ꞵ, TNF-α, etc.). Chronic exposure to these molecules 
promotes aberrant signalling in HSPCs induced via TLR, TNFR, IL-1R1/ IL1RAP receptors. This may lead 
to pyroptosis (inflammatory cell death), myeloid skewing, induction and accumulation of mutations in 
various genes, resulting in clonal haematopoiesis. The inflammatory conditions are enhanced with pyroptosis 
and the inflammatory molecules generated by mutant HSPCs and immune response in the bone marrow. 
Eventually, anti-inflammatory milieu is established with strong immune suppressive actions of MDSCs and 
Tregs, altogether enabling immune evasion and accumulation of the malignant clones, thus resulting in the 
leukemic transformation. HSPC – Haematopoietic stem cells and progenitors, MSC – mesenchymal stem 
cells, DAMPs – damage-associated molecular patterns,  ROS – reactive oxygen species, RNS – reactive 
nitrogen species, IL – interleukins, TNF-α – tumour necrosis factor α, TGF-ꞵ – tumour growth factor ꞵ, M – 
macrophages, TLR – Toll-like receptors, TNFR – TNF receptor, IL-1R1 – Interleukin-1 receptor 1, IL-1RAP 
– Interleukin-1 receptor associated protein, IL-6R – interleukin 6 receptor, DC – dendritic cells, NK – natural 
killer cells, T – T cells, Treg – regulatory T cells, MDSCs – myeloid-derived suppressor cells, MDS – 
myelodysplastic syndromes, AML – acute myeloid leukaemia. SF3B1 – splicing factor 3B subunit 1, TET2 – 
tet methylcytosine dioxygenase 2, SFRS2 – splicing factor, arginine/serine-rich 2, ASXL1 – additional Sex 
Combs Like 1, DNMT3A – DNA methyltransferase 3 alpha, U2AF1 – U2 small nuclear RNA auxiliary 
factor 1. Adapted from (Winter et al., 2020). 
 
Indeed, clonal haematopoiesis of indeterminate potential (CHIP) is an observation 
with 10% prevalence in >70 years old individuals. The bone marrow of individuals with 
CHIP contains HPSCs with mutation or mutations commonly associated with MDS, 
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however, these individuals do not manifest the symptoms of MDS (Bewersdorf et al., 
2019). Therefore, the blast mutations are the feature of MDS, but the onset of the disease is 
stimulated via different stimuli. In recent work, the authors showed that HPSCs clones 
overexpressing TRAF6, which is often overexpressed as a result of mutations in HSPCs in 
MDS, show no growth advantage in normal bone marrow. However, once inflammatory 
stimuli are introduced into the bone marrow then TRAF6-overexpressing clones thrive 
(Muto et al., 2020). These results indicate that chronic inflammation is likely an essential 
factor during the onset of the disease. Once established, inflammatory signalling promotes 
changes in the bone marrow, including accumulation of MDSCs and other cell types 
(Winter et al., 2020), which altogether initiate stress response resulting in pro-
inflammatory cell death and oxidative stress, both possibly causing DNA damage and the 
increase in mutational burden of blasts associated with MDS progression  
(Chen et al., 2013; Guida et al., 2014; Yang et al., 2015).  
The role of MDSCs in pathogenesis of MDS is crucial. MDSCs promote pyroptosis 
in HSCPs (Chen et al., 2013), which maintains pro-inflammatory milieu in the bone 
marrow and enhances their accumulation. However, the function of MDSCs is to inhibit 
the immune response. In doing so, accumulated MDSCs promote anti-inflammatory 
conditions; hence the bone marrow of the high-risk MDS is highly immunosuppressive. 
This enables the accumulation of malignant blasts and subsequent leukemic transformation 
(Winter et al., 2020; Yang et al., 2015). MDSCs promote their function via secretion of 
small molecules, intercellular contacts, and cytokine signalling. Hence to understand the 
pathological changes of the bone marrow in MDS, the role of MDSCs and their secreted 
components might provide important answers.   
 
2.12 Suprabasin  
Suprabasin (SBSN) represents a recently identified oncogene of unknown function. Since 
SBSN is not a well-studied gene, its role in physiology and pathology is largely 
undiscovered. It is proposed that SBSN encoded proteins are secreted signalling molecules, 
yet the receptor(s) are unknown. SBSN is associated with cancer, but causes of its aberrant 
expression are yet to be uncovered.  
 SBSN is physiologically expressed in stratified epithelia in both mice and human. 
Skin is the main expression site of SBSN (Matsui et al., 2004; Park et al., 2002), but other 
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organs with SBSN expression are also described. These include thymus, tonsils, 
esophagus, uterus, and vagina. Additionally, SBSN was shown to be expressed or elevated 
in various tissues following stress events, these include, for instance, astrocytes of human 
brain following lipopolysaccharide (LPS) treatment (Ichinose et al., 2018) or murine 
urothelial cells in close proximity of intracellular uropathogenic Escherichia coli colonies 
(Reigstad et al., 2007). Both SBSN-inducing stimuli suggest that innate immune response 
could be at least partially responsible for elevated SBSN expression. Interestingly, muscle 
biopsies of exercising alaskan dogs showed elevated SBSN mRNA levels, as well as 
mRNAs of genes corresponding to inflammatory response (Brass et al., 2009). These 
examples seem rather obscure, yet another study showed elevated SBSN mRNA levels in 
carotid arteries of sheep exposed to high altitudes, hence long-term hypoxia resulting in 
acclimatization (Goyal and Longo, 2014). Authors noted that among other 57 elevated 
mRNA genes, some of them are targets of LPS-induced signalling (Goyal and Longo, 
2014). Altogether, inflammatory response might play a role in SBSN expression under 
pathological conditions.  
Inflammatory signalling, as already described, is an essential factor in tumour 
progression and many aspects associated with tumour diseases. Hence it is no surprise that 
SBSN is upregulated also in cancer. Increased SBSN expression was shown in esophageal 
squamous cell carcinoma (ESCC) (Zhu et al., 2016) and tumour endothelial cells of colon 
cancer (Alam et al., 2014). SBSN transcript levels were elevated in NSCLC (Glazer et al., 
2009), ESCC (Zhu et al., 2016), and metastatic head and neck cancer cells (Liu et al., 
2019). Next, SBSN expression was also observed in in vitro cancer models, such as 
glioblastoma (Formolo et al., 2011) and salivary gland cancer cell lines (Shao et al., 2012), 
where its expression was associated with elevated invasiveness, and anchorage-
independent growth, respectively. Last but not least, oral squamous cancer cells elevated 
SBSN mRNA following treatment with Porphyromonas gingivalis lysate (Liu et al., 2020), 
once again supporting the role of innate immune response and inflammation in regulation 
of SBSN expression. Note, in the later study, P.gingivalis infection was shown to be 
responsible for immune evasion of the cancerous cells.  
Human SBSN encodes three protein isoforms (Figure 6). All represent secreted 
molecules. Human isoform-2 is a fully spliced version, isoform-1 contains intron-1 
retention, and isoform 3 is missing exon-2. Intron-1 retention in SBSN-1 encodes a highly 
conserved domain containing Ala-/Gly-/His-rich repeats. In general, repetitive regions are 
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associated with mechanically resistant proteins, hence corneocyte-expressed SBSN proteins 
were proposed as important components of cornified envelope, the outer structure of 
corneocytes essential for the function of skin (Park et al., 2002). Yet, this role was not 
clearly supported by other studies.  
Human SBSN isoform-2 is the isoform associated with oncogenic role of SBSN 
(Takahashi et al., 2020; Zhu et al., 2016). Importantly, mouse isoform corresponding to 
human SBSN isoform-2 has not been identified (Mus musculus), thus mouse probably 
lacks this isoform (Hunt et al., 2018; Park et al., 2002). This is an important observation 
when comparing human and mouse SBSN functions. Both human and mouse possess 
isoform-3, but this isoform is the least studied one.  
 
Figure 6. Transcripts of human SBSN isoforms. Human SBSN gene encodes three isoforms. The longest 
isoform-1 retains intron-1, this results in retention of a long repeat containing Ala/Gly/His-region. Isoform-2 
is associated with the oncogenic potential of SBSN. This isoform is missing in Mus musculus. Isoform-3 
lacks exon-2 and is the least studied isoform of SBSN. White boxes mark untranslated regions. Ala – alanine, 
Gly – glycine, His – histidine.  
 
SBSN was shown to stimulate several signalling cascades. SBSN-2 induced Wnt 
pathway via phosphorylation of GSK3ꞵ and subsequent ꞵ-catenin stabilization in ESCC 
(Zhu et al., 2016). This study originally proposed its role as an oncogene, since SBSN-2 
expressing tumours were larger and markedly more vascular. SBSN-2 treatment induced 
HUVEC sprouting and migration via activation of p38 pathway, but Akt also showed 
elevated phosphorylation, yet it was not essential for the observed phenotype  










































colon cancer, which further supports its association with vascular changes in cancer  
(Alam et al., 2014). However, in TEC, this effect was mediated via Akt phosphorylation.  
Description of SBSN in this chapter provides information necessary to understand 
the results of two research articles which are parts of this thesis. We complied all current 
knowledge of SBSN in a yet to be published review. For the interested reader, we provide 
this review at the end of this work. 
Certainly, SBSN holds a great undiscovered potential. It is associated with cancer 
and inflammation and promotes activation of multiple signalling pathways responsible for 
survival, differentiation, and importantly, therapy resistance. A lot remains to be uncovered 
in search for the role of SBSN in cancer progression. We hope our studies presented in this 



















3. Aims of the study 
The thesis contains two research articles. In these we attempted to elucidate several topics. 
In the first research article we aimed to:  
 Describe the features of therapy-surviving cancer cells with low-adherent 
phenotype induced with clinically relevant radiotherapy and chemotherapy regimes 
in vitro.  
 Elucidate the role of SBSN in low-adherent therapy-resistant cancer cells. 
 
In the second article we aimed to: 
 Identify the prognostic potential of SBSN expression in the bone marrow of 
myelodysplastic syndromes patients. 
 Identify the source of SBSN expression in the bone marrow of myelodysplastic 
syndromes patients.  
 
The connection of both topics depicted in the research articles is explained in a chapter 




4. List of utilized methods 
Here is a list of individual methods utilized in both articles presented below. The 
descriptions of the methods are within method sections of particular articles. 
 Cell cultures 
 Colony-forming assay 
 Detection of apoptosis using fluorescence activated cell sorting (FACS) 
 Dual-luciferase reporter assay 
 Enzyme-linked immunosorbent assay 
 Fluorescence-activated cell sorting 
 Generation of the stable SBSN-expressing cell line via a lentiviral system 
 Human bone marrow and peripheral blood plasma samples preparation 
 Immunohistochemistry  
 Indirect immunofluorescence 
 Isolation of bone marrow mononuclear cells 
 Magnetic-activated cell sorting (MACS) 
 Molecular cloning 
 Mouse spontaneously metastasizing 4T1 mammary gland cancer cell line  
 Proteomic analysis 
 Quantitative real time PCR (RT-qPCR) 
 Gene knockdown with RNA interference 
 SDS/PAGE and immunoblotting 
 Transient transfection  







5. The first article 
The first article is entitled: “Interferon-regulated suprabasin is essential for stress-induced 
stem-like cell conversion and therapy resistance of human malignancies”  
(Hubackova et al., 2019).  
The article has been published in 2019 in Molecular Oncology (2019 2-Year Impact 
Factor: 6.574). 
Authors: This article has shared co-first authorship. The first authors are Soňa Hubáčková 
(SH), Miroslav Přibyl (MP), and Lenka Kyjacová (LK). Both SH and LK started the work 
and contributed in first 2-3 years (approximately 2013-2016). Subsequently, MP 
contributed in following 3 years (2016 – 2019).  
  
Summary: Work presented in the article follows up a previous article by Kyjacova et al. In 
the previous work, authors utilized prostate cancer models irradiated with clinically 
relevant radiation dosage to induce therapy-resistant fraction of cancer cells with low-
adherent phenotype. These anoikis-resistant non-cycling cells expressed markers of 
stemness and required active Erk and Akt signalling for their survival (Kyjacova et al., 
2014).  
In the following study presented here (Hubackova et al., 2019), we expanded the 
knowledge of therapy-induced low-adherent cells. We used additional model cell lines and 
showed that besides radiotherapy, 5-AC also induced the similar phenotype. The 
expression profiles of low-adherent cells showed hundreds of dysregulated genes, 
including upregulation of genes responsive to IFN treatment. Indeed, IFNγ treatment 
induced low-adherent phenotype as well. Importantly, SBSN was among the upregulated 
genes, and we showed, that its expression is essential for low-adherent cells, since 
downregulation of SBSN expression resulted in decrease of low-adherent cells abundance 
following the therapy treatments.  
 
MP contribution: MP performed experiments to obtain data presented in these figures: 
Figure 3I, J; Figure 4G, H, I; Figure 5E, F, G; Figure 6A (electrophoresis was performed 
by SH), B, C, D; Supplementary Figure 1B; Supplementary Figure 3A, B; Supplementary 
Figure 4E, F, G, H, I; Supplementary Figure 5E. MP also assisted with writing the article. 
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6. Linking the publications  
In the first publication (Hubackova et al., 2019) we showed, that 5-AC treatment promotes 
therapy-resistant phenotype of cancer cells. 5-AC-induced SBSN and downregulation of 
SBSN expression reduced low-adherent cells abundance, suggesting its role in promoting 
the phenotype or survival of low-adherent cells.  
 Since 5-AC is the first-line treatment in the high-risk MDS, we asked whether 5-
AC induces SBSN in the bone marrow of MDS patients and what would be the effect of 
this change. 
 Indeed, we showed that SBSN is markedly elevated in the bone marrow of a 
subgroup of high-risk MDS patients. Importantly, SBSN expression was mediated by 
MDSCs and not by 5-AC-therapy (Pribyl et al., 2020). Results and discussions are 




7. The second article  
The second article is entitled: “Aberrantly elevated suprabasin in the bone marrow as  
a candidate biomarker of advanced disease state in myelodysplastic syndromes”  
(Pribyl et al., 2020).  
The article has been published in 2020 in Molecular Oncology (2019 2-Year Impact 
Factor: 6.574). 
Authors: MP is the first author of this article.  
Summary: Following the previous study (Hubackova et al., 2019), we asked whether MDS 
patients show elevated SBSN in the bone marrow. Importantly, 5-AC is used as the first-
line treatment for the high-risk MDS and 5-AC induced the expression of SBSN in vitro 
(Glazer et al., 2009; Hubackova et al., 2019). Indeed, SBSN was elevated in the bone 
marrow of MDS, but this was not caused by 5-AC therapy. Hence, a cellular compartment 
is responsible for the expression. Indeed, SBSN aberrant expression was mediated by 
MDSCs in the bone marrow of a subgroup of the high-risk MDS patients. Additionally, 
elevated SBSN levels negatively correlated with T cells abundance and CCL2.  
 
MP contribution:  The experiments in this publication were predominantly performed by 
MP. Except for SBSN, other cytokines and cell counts in patient cohort #3 were measured 
by Alena Moudra (AM) in her previous study (Moudra et al., 2016). SH performed 




8. Discussion  
8.1 Therapy promotes therapy-resistant phenotype  
Metastatic diseases are responsible for most of the cancer-caused deaths. Upon overcoming 
the state of dormancy, disseminated tumour cells promote growth of micrometastases 
which may turn into overt metastases. Adaptive non-mutational mechanisms are also 
induced with therapy. These may be responsible for cancer evolution (Russo et al., 2019), 
resistance (Pisco et al., 2013), spreading (Aldonza et al., 2020), and subsequently enabling 
cancer recurrence. Our results showed that the commonly used cancer therapy treatments, 
such as fractionized irradiation and 5-AC chemotherapy promoted therapy-resistant non-
cycling anoikis-resistant phenotype of cancer models in vitro. We refer the cells with this 
phenotype as ’low-adherent cells’. Importantly, we observed that low-adherent cells are 
able to reattach and re-enter the cell cycle which resulted in growth of colonies. Thus 
partially resembling the events of tumour dissemination proposed in vivo.  
Dormancy is a non-proliferative state; this means that the dormant tumour cells do 
not promote the growth of metastases unless the dormancy state is overcome. Three types 
of dormancy states are described (angiogenic, immune, and cellular dormancy). Novel 
blood vessels provide nutrients and oxygen supply for tumour cells. Subsequently, the 
requirements for angiogenic dormancy exit are met. Upon immune suppression, immune 
dormancy is passed (Jimsheleishvili et al., 2014; Strauss and Thomas, 2010). Immune 
suppression is mediated via immune suppressive cells activity (e.g. MDSCs), but possibly 
by tumour cells as well. Cellular dormancy remains the least understood type of described 
dormancies. Certainly, surpassing angiogenic dormancy was proposed to enable surpassing 
cellular dormancy as well (Sosa et al., 2014). Since cellular dormancy is likely an intrinsic 
program of dormant tumour cells, models to study this phenomenon would be useful.  
Altogether, we showed that both irradiation and 5-AC therapy, both commonly 
utilized in cancer treatment, promote therapy-resistant dormant-like state of cancer cells. 
This model could provide useful knowledge of cellular dormancy, the least understood 




8.2 IFN pathway is essential for therapy-resistant phenotype 
Besides previously observed features of dormant tumour cells, such as therapy resistance, 
inhibited proliferation, and stemness, low-adherent cells showed increased expression of 
MHC I components (namely HLA-C, E, G), which has been supported previously 
(Mahnke et al., 2005). Additional IFN-responsive genes’ transcripts were elevated, 
suggesting IFN pathway is induced in low-adherent cells. Indeed, IFNγ treatment, but not 
IFNꞵ, promoted low-adherent phenotype, similar to irradiation or 5-AC described above. 
This suggests that IFN pathway is essential effector pathway for all three treatments 
inducing low-adherent cells. This supports the notion presented here that irradiation, 5-AC, 
or IFNγ treatments induce the same phenotype. Additionally, Erk inhibition resulted in 
reduction of low-adherent cells abundancy as well, which indicates that IFN pathway 
induces Erk signalling, suggesting that Erk pathway is also essential in the development of 
low-adherent phenotype.  
IFNγ signalling induces MHC I components expression, enforcing cells to present 
antigens (Basham and Merigan, 1983; Kalbasi and Ribas, 2020). This could potentiate 
clearance via immune cells. Conversely, mechanisms enabling immune evasion are also 
promoted via IFNγ signalling, such as PD-L1 upregulation (Bellucci et al., 2015; Garcia-
Diaz et al., 2017).  
IFNγ is essential in anti-tumour activity; hence entering the state of dormancy could 
represent a mechanism of resistance of cancer cells against immune surveillance-promoted 
clearance. The response of tumour cells to IFNγ resulting in immune suppression and 
evasion has been documented. IFNγ promoted cell cycle arrest, quiescence, and dormancy, 
or dormant-like states (Bosserhoff et al., 2004; Liu et al., 2017; Müller-Hermelink et al., 
2008). Besides, chronic stimulation with IFNγ resulted in ICI therapy resistance as well as 
radiotherapy resistance (Benci et al., 2016).  
5-AC inhibited proliferation and promoted a dormant-like state in cancerous cells, 
including CSCs (Tsai et al., 2012). Additionally, 5-dAC induced IFN response in colon 
cancer models (Karpf et al., 1999), as well as MHC I glycoproteins expression (Rhee et al., 
2002). Subsequent studies confirmed IFN pathway stimulation in NSCLC models 
following the treatment with 5-AC (Wrangle et al., 2013). Therefore, 5-AC likely promotes 
dormancy via IFN pathway.  
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These results indicate that irradiation, 5-AC, or IFNγ induce Erk and IFNγ 
signalling. Both pathways are essential for the phenotype, since their inhibition disrupts it.  
 
8.3 SBSN expression is essential for low-adherent cells 
Among hundreds of differentially expressed genes we selected SBSN to investigate more 
deeply. SBSN is a proposed oncogene, which is suggested by several reports  
(Takahashi et al., 2020; Zhu et al., 2016). Aberrant expression of SBSN is associated with 
cancer, specifically with invasiveness of glioblastoma cell line (Formolo et al., 2011), 
anchorage-independent growth in vitro (Shao et al., 2012), or enhanced proliferation in 
vitro and in vivo (Zhu et al., 2016). Besides that the knowledge of SBSN is lacking. 
Importantly, the oncogenic role of SBSN was attributed to its isoform-2 (Zhu et al., 2016).  
 Induction of SBSN transcript with 5-AC was documented (Gaykalova et al., 2012). 
We showed that SBSN expression is induced with irradiation, 5-AC, or IFNγ treatments. 
This has not been documented before. Erk pathway promoted the expression of SBSN and 
Erk inhibition suppressed the expression. BORIS was shown to promote SBSN transcripts 
elevation (Gaykalova et al., 2012) and 5-AC induced BORIS levels (Karpf, 2006), hence 
5-AC induced SBSN expression via BORIS in our model is also likely. 
 In low-adherent subpopulation of therapy-surviving cells, we observed SBSN 
isoforms with ~70kDa. This suggests SBSN-1 is induced in low-adherent cells. One report 
indicates, that SBSN proteins may undergo posttranslational modifications including cross-
linking mediated by transglutaminases 2 and 3 (Park et al., 2002). Hence, we cannot 
exclude other possibilities, such as SBSN-2 crosslinking and other cross-reactions. 
Nevertheless, we also cannot exclude a possibility of functional difference of individual 
isoforms. SBSN-2 promotes proliferation; however SBSN-1 might promote therapy or 
anoikis resistance, both the features of our model. Indeed siRNA-mediated knockdown of 
SBSN resulted in markedly reduced numbers of low-adherent cells following their 
induction. This suggests that SBSN is essential to manifest the therapy-induced low-
adherent phenotype of cancer cells.  
Indeed, SBSN expression induced Akt, Wnt, or p38 pathways in various models. Wnt 
signalling is associated with therapy-resistance and cancer stemness (Malanchi et al., 2012; 
Pisco et al., 2013; Vermeulen et al., 2010; Wang et al., 2015b) and p38 is crucial for 
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maintaining cellular dormancy (Balz et al., 2012; Bartkowiak et al., 2010; Gao et al., 2017; 
Kobayashi et al., 2011; Marshall et al., 2012; Masiero et al., 2011). Hence activation of 
Wnt and p38 pathway via SBSN could explain these features observed in low-adherent 
cells. These require further investigation.  
   
8.4 SBSN is elevated in tumour samples and cancer tumour cells 
Aberrant expression of SBSN was documented in several tumour types, such as NSCLC 
(Glazer et al., 2009), salivary gland adenoid cystic carcinoma (Shao et al., 2012), and 
ESCC (Zhu et al., 2016). SBSN was also aberrantly elevated in TEC of renal cancer and 
colon cancer where it induced Akt activity (Alam et al., 2014).  
 We supported previously documented increase of SBSN mRNA levels in colon 
cancer (Alam et al., 2014). Importantly, we identified increased SBSN mRNA levels in 
large number of ovarian carcinoma samples. Additionally, SK-OV-3 ovarian carcinoma 
cell lines showed SBSN expression under standard conditions.  
 As we proposed, SBSN-expressing cells with low-adherent phenotype resemble 
cellular dormancy. Interestingly, spontaneously metastasizing murine mammary carcinoma 
4T1 model elevated SBSN mRNA levels in circulating tumour cells. Circulating tumour 
cells travel through bloodstream prior settling in a metastatic niche, hence these results 
further support the role of SBSN in dormancy and tumour dissemination.  
 
8.5 SBSN is elevated in MDS patients  
5-AC therapy has been a first-line treatment in MDS for multiple years. Unfortunately, 
only 50% of patients respond to the therapy (Santini, 2019). In our previous study, we 
showed that 5-AC induced therapy-resistant phenotype. Since these therapy-resistant 
cancer cells required SBSN expression for their survival, we asked whether SBSN is 
expressed in the bone marrow of MDS patients and whether the therapy affects these 
changes.  
 We observed elevated SBSN mRNA levels in MDS patients as well as elevated 
SBSN protein levels in the bone marrow plasma samples of MDS patients. We compared 
SBSN mRNA or protein levels between two groups of patients, the patients undergoing  
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5-AC therapy and patients without the therapy. Interestingly, no significant difference in 
SBSN expression between these groups was observed. This indicates that 5-AC therapy 
does not markedly affect the SBSN expression in the bone marrow of MDS patients. 
Therefore, SBSN expression is inherent with pathophysiology of MDS. 
  
8.6 SBSN in MDS patients’ stratification  
In a recent review publication (Winter et al., 2020), authors stressed that failures of clinical 
trials in MDS are likely caused by insufficient stratification of patients. This means that the 
syndromes themselves are more diverse than the current stratification of patients allow. 
Indeed, every patient is different, but based upon current stratification systems we can 
assume that within the prognostic groups are subgroups with varying predispositions 
towards treatments. A group of patients with the same prognosis might be recruited into  
a trial, but this group is consisted of patients with varying bone marrow environments and 
varying mutations, both affecting the disease progression and response to the treatment.  
So far, only two mutated genes made it into IPSS-R clinical stratification, these are SF3B1 
and TP53 (Haferlach et al., 2014; Hasserjian, 2019). Despite the identification of various 
mutations, no other showed prognostic potential. Additionally, biomarkers in MDS have 
not been identified. Thus identification of biomarkers would allow better stratification. 
Subsequently, this would provide more accurate recruitments into clinical trials and 
identification of efficient therapies for specific subgroups.  
Upon assigning our cohort of patients into their prognostic groups we noticed that 
patients with the highest SBSN levels in the bone marrow were predominantly poor-
prognosis patients (Int-2 according to IPSS, and EB-2 according to WHO classification), 
but not all poor-prognosis patients showed elevated SBSN levels. This indicates that  
a subgroup of poor-prognosis MDS patients has elevated SBSN protein levels. 
Interestingly, AML patients showed SBSN levels comparable to healthy donors or the low-
risk MDS patients, indicating that SBSN expression is lost following the leukemic 
transformation. Indeed, in a group of three poor-prognosis MDS patients, we showed that 
following the transformation into AML, SBSN levels were markedly reduced. Hence, 




Additionally, SBSN protein levels in the peripheral blood corresponded to SBSN 
protein levels in the bone marrow. Since the bone marrow biopsies are currently the only 
option in determining the patients’ progression, SBSN levels in the peripheral blood 
represent an accessible biomarker of the disease. Whether SBSN levels in the peripheral 
blood could be utilized as markers of the disease progression require further investigation.  
 
8.7 SBSN is expressed by MDSCs in the bone marrow of MDS 
To identify the cellular source of SBSN expression in the bone marrow of MDS, we 
performed immunohistochemistry and immunofluorescence staining of SBSN in the bone 
marrow sections and smears. We also performed fluorescence-activated cells sorting to 
isolate specific subpopulations from the bone marrow of MDS and control group patients. 
Utilizing these techniques we identified a specific myeloid compartment, MDSCs, as  
a cellular source of SBSN expression in the bone marrow of MDS.  
 Interestingly, eMDSCs and PMN-/MN-MDSCs showed the highest levels of SBSN 
mRNA in MDS. This indicates that MDSCs are the source of aberrant expression of SBSN 
in the bone marrow of MDS. Monocytes and neutrophils-containing ficoll-isolated high-
density fraction showed lower fold change levels of SBSN mRNA. These cells are likely 
responsible for basal SBSN levels observed in control groups and low-risk MDS. 
Importantly, abundance of eMDSCs, PMN-/MN-MDSCs, or monocytes was not 
significantly different between MDS and control groups. Hence, elevated SBSN expression 
is not mediated by increased MDSCs numbers, but rather by elevated stimuli inducing the 
expression in MDSCs. Identifying the stimuli responsible for these observations require 
further effort.    
 
8.8 SBSN and immune system 
Our results indicate that SBSN is expressed by MDSCs in the bone marrow of MDS. These 
cells represent an immune suppressive compartment. MDSCs are associated with cancer; 
however their role in pathobiology and physiology is also crucial. For example they play 
an important role in pregnancy; where MDSCs prevent T cells reaction towards foetus, 
thus establishing the tolerance (Bartmann et al., 2016; Kang et al., 2016; Nair et al., 2015). 
Importantly, MDSCs are detrimental in MDS pathogenesis. MDSCs-secreted S100A8/9 
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alarmins induced pro-inflammatory cell death of erythroid precursors (Chen et al., 2013). 
This results in reduced development of erythrocytes, thus causing anaemia and increase 
inflammation in the bone marrow, which significantly contributes to the disease 
pathogenesis and progression.  
 S100A8/9 represents innate immune response proteins commonly elevated 
following bacterial infection (Wang et al., 2018). SBSN, as we suggest, is likely 
inflammation and/or innate immune responsive gene, since bacterial components induced 
SBSN mRNA levels. We cannot state what stimuli are promoting SBSN expression in 
MDSCs yet, but these stimuli are certainly changing among various patients, thus altering 
the level of SBSN expression.   
 We can only speculate what signals promote SBSN expression in MDSCs. The bone 
marrow milieu of MDS undergoes dramatic changes during the progression of the disease. 
Levels of various cytokines shift; cellular composition affects and promotes these changes 
as well as therapy (Moudra et al., 2016; Winter et al., 2020; Yang et al., 2015).   
The changes in cytokines and inflammatory molecules are the crucial factors in 
MDS which receive more attention now than ever. Altering the microenvironment of the 
bone marrow strongly affects the cellular components including HSCPs. Since SBSN is  
a signalling molecule, we can assume that its aberrant expression affects these cells as 
well. SBSN induced signalling pathways (e.g. Akt, Wnt, or p38), and is associated with 
therapy resistance, as we showed in previous study.  
Recently, the reduced expression of SBSN was detected in skin of atopic dermatitis 
patients. IL-4/IL-13-induced apoptosis of keratinocytes in human living skin equivalents 
model following SBSN knockdown. This suggests that symptoms associated with the 
condition are promoted via dysregulated Th2 lymphocytes-induced response in human skin 
(Aoshima et al., 2019). Thus, there is a role for SBSN in immune regulation. Furthermore, 
SBSN-null mice lacked Treg generation in the spleen in response to low-dose nickel 
challenge (Nakazawa et al., 2020). Mechanisms were not clarified, yet this report further 
supports the role of SBSN in immune regulation, which is in accordance with our results 






To conclude, we showed the observations showing that therapy promotes therapy-resistant 
phenotype. Besides irradiation, 5-AC induced IFN signalling-dependent therapy-resistant 
anoikis-resistant phenotype in various cancer cells lines. Additionally, IFNγ treatment 
induced similar phenotype. Therefore, extrinsic approaches targeting the cancer cells, as 
well as intrinsic cancer-eradicating mechanisms, such as immune-surveillance, both 
promote therapy resistance in cancer cells. Understanding underlying mechanisms 
represent challenges of current cancer therapies.  
 Among hundreds of differentially expressed genes in therapy-resistant low-adherent 
cells, we selected oncogene SBSN to determine its role in the phenotype. Knockdown of 
Erk/IFNγ-regulated SBSN markedly reduced the abundance of low-adherent cells, 
indicating that SBSN is a crucial mediator of therapy-resistant anoikis-resistant phenotype.  
 5-AC promotes SBSN expression and 5-AC is a first-line therapy in MDS. Indeed, 
we showed aberrant expression of SBSN in the bone marrow of MDS, but this was not 
mediated by 5-AC therapy. Instead, the expression of SBSN was mediated by MDSCs in 
the bone marrow of a subgroup of MDS patients. 
 MDSCs are crucial in MDS pathogenesis and progression. Understanding their role 
in the context of MDS is essential in order to identify novel therapeutic approaches. 
Identifying efficient treatments for MDS is problematic. This is a result of insufficient 
stratification which is due to lack of biomarkers (Winter et al., 2020).  
 Here we identified SBSN as a candidate biomarker for a subgroup of poor-
prognosis MDS patients. Elevated SBSN levels marked reduced abundance of T cells and 
CCL2 levels in the bone marrow. This could indicate a lower potential for immune-based 
therapies requiring T cells infiltration. Additionally, patients with the highest SBSN levels 
are likely pre-leukemic, hence a specific approach might be suitable for this group of 
patients, once supported with a larger cohort of patients.  
 Altogether, our results indicate that SBSN plays a role in therapy resistance and its 
associated phenotype. SBSN is upregulated in therapy-induced therapy-resistant cancer 
cells, and its aberrant expression in the bone marrow of MDS marks reduced T cells 
infiltration. Recent observations showed that SBSN inhibited T-cell-induced apoptosis and 
Treg development.   
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10. Perspectives  
There are several emerging questions that need to be addressed in future studies. 
Importantly, the mechanism of SBSN-mediated survival in low-adherent cells requires 
deeper understanding. SBSN is reported to induce several signalling cascades that were not 
addressed in our study, such as Wnt or p38 pathway. Thus it would be of interest to 
elucidate their participation in the phenotype.  
Given the receptors of SBSN are not known; certainly these are of great 
importance. SBSN isoforms represent signalling molecule, thus revealing their receptors 
would provide hints for future studies deciphering physiological and pathological function 
of SBSN. Systemic effects of SBSN are likely to occur, especially in human malignancies, 
hence knowing the receptors, systemic targets could be evaluated as well.  
 We showed that SBSN represents a candidate biomarker in MDS. In follow up 
studies we would like to utilize a greater cohort of patients and to follow the changes of 
SBSN levels over time in individual patients. This is required to provide a comprehensive 
picture of SBSN level changes and its potential as a biomarker of the disease progression. 
Certainly, we would like to elucidate whether sudden reduction of SBSN levels in the bone 
marrow of MDS predicts the onset of the leukemic transformation prior elevation of  
the blast count. This also requires a prolonged study.  
 Since SBSN levels showed a significant anti-correlation with T cells and CCL2, we 
can speculate that patients with the highest SBSN levels might not benefit from immune-
based approaches requiring T cell infiltration, such as autologous adoptive T cell transfer, 
ICI, or DC therapy. Once recruited into clinical trials applying these approaches, SBSN 
levels could be measured and evaluated together with the trials.  
 SBSN represents an interesting target for future studies, yet we can assume there are 
multiple problems to be solved. The posttranslational modifications of SBSN isoforms are 
elusive. The posttranscriptional regulations of SBSN expression are untouched. 
Mechanisms responsible for aberrant expression of SBSN in human malignancies are also 
undiscovered. To embrace these attempts we compiled all current knowledge of SBSN in  
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